Cell Biotech Co Ltd
KOSDAQ:049960
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cell Biotech Co Ltd
Net Income (Common)
Cell Biotech Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cell Biotech Co Ltd
KOSDAQ:049960
|
Net Income (Common)
₩10.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-5%
|
|
|
Celltrion Inc
KRX:068270
|
Net Income (Common)
₩1T
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Net Income (Common)
-₩15.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Net Income (Common)
-₩32.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Net Income (Common)
₩141.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Net Income (Common)
-₩37.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Cell Biotech Co Ltd
Glance View
Cell Biotech Co., Ltd. engages in the manufacture, research and development of probiotics lactobacillus products. The company is headquartered in Gimpo, Gyeonggi-Do. The company went IPO on 2002-12-13. The firm's products include lactic acid bacteria (LAB) powders and finished products containing LABs. Its LAB powders are used as raw materials in foods and medicines for the functions of immunization enhancement and digestion improvement. Its finished products containing LABs are used for intestinal health improvement, carcinogen inhibition, calcium supplement and others. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Cell Biotech Co Ltd's Net Income (Common)?
Net Income (Common)
10.1B
KRW
Based on the financial report for Dec 31, 2025, Cell Biotech Co Ltd's Net Income (Common) amounts to 10.1B KRW.
What is Cell Biotech Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-5%
Over the last year, the Net Income (Common) growth was -33%. The average annual Net Income (Common) growth rates for Cell Biotech Co Ltd have been 7% over the past three years , 26% over the past five years , and -5% over the past ten years .
